Navigation Links
ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Date:5/17/2010

LEUVEN, Belgium and LUND, Sweden, May 17, 2010 /PRNewswire-FirstCall/ --

- Trial to Study Patients with Colorectal and Ovarian Cancer

ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers. ThromboGenics and co-development partner BioInvent will receive a milestone payment of EUR10 million from Roche under the terms of the strategic alliance agreement signed in June 2008. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of all revenue from the alliance with Roche for this anti-cancer antibody.

This trial is a multi-centre, open-label (monotherapy), dose-finding study with intravenous TB-403. The primary objective of the study will be to establish the TB-403 concentration-pharmacodynamic (PD) effect relationship using DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) and to identify the minimally PD effective dose. The trial will recruit up to 50 patients across three European sites.

With the start of this study, Roche will assume responsibility for all future development of TB-403, continuing the work started by ThromboGenics and BioInvent. A Joint Steering Committee made up of representatives from Roche, ThromboGenics and BioInvent will continue to oversee research and development activities. In addition, Roche will continue to provide funding to ThromboGenics and BioInvent for re
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, ... the American Association of Tissue Banks (AATB), it ... Chief Executive Officer. Accreditation follows an ... a specially trained AATB inspector.  It establishes that ... within the facility meets or exceeds the standards ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional ... towels and tissue for a wide range of ... of its product lines in healthcare, including hospitals, ... Georgia-Pacific Professional is introducing its healthcare products and ... Professional understands the importance of infection control in ...
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, one ... , has launched FluFree.com, a website designed to ... For 20 years, Passport Health has provided ... flu. The launch of FluFree.com is designed to address ... the number of people who actually chose to get ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... Jan. 23, 2012  PLC Systems Inc. (OTC: PLCSF), a ... successful enrollment of the first patient in the CIN-RG ... of its RenalGuard Therapy® and RenalGuard System™ in the ... step in the process to secure regulatory approval by ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... of cancer, announced today that it has secured ... including IDG-Accel China Growth Fund II L.P. ("IDG"), ... W. Mak, Director of The Campbell Family Institute ...
Cached Medicine Technology:First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 2First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 3EntreMed Secures $10 Million Strategic Financing 2EntreMed Secures $10 Million Strategic Financing 3EntreMed Secures $10 Million Strategic Financing 4EntreMed Secures $10 Million Strategic Financing 5
(Date:9/30/2014)... September 30, 2014 A group of Americans ... combat an epidemic that, left unchecked, could create a catastrophic, ... not headed to Africa. John Rogers, the Executive Director the ... Korea to fight a disease most think mankind conquered long ... 80 years ago is on the comeback in several countries ...
(Date:9/30/2014)... Beach, Florida (PRWEB) September 30, 2014 Two ... make the treatment of gum disease a far ... of the past. , “If you’ve ever felt electric shock ... cream or sip a cold beverage, it’s possible you already ... Salisbury , who is a general dentist in West Palm ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Medicare should cover low-dose computed ... for the disease, a coalition of more than 60 ... includes the Lung Cancer Alliance, the Society of Thoracic ... Society and the American Society of Clinical Oncology, made ... U.S. Centers for Medicare & Medicaid Services (CMS). ...
(Date:9/30/2014)... of Defense has made progress in reducing the stigma ... depression and post-traumatic stress disorder, but more improvement is ... , Despite efforts of both the Defense Department and ... many service members still do not seek needed care ... a concerted effort to promote treatment as a way ...
(Date:9/30/2014)... ANN ARBORThe discovery of a gene mutation that causes ... development of drugs that block the rapid, unstoppable cell ... at the University of Michigan and the U-M Health ... devastating disease dyskeratosis congenita, in which precious hematopoietic stem ... DC age prematurely and are prone to cancer and ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2
... , TUESDAY, Jan. 12 (HealthDay News) -- An experimental ... study shows. , The drug, DBZ, currently in clinical ... have side effects on the lining of the lower ... to those seen in Barrett,s esophagus, a condition that ...
... two ,good, copies slows age-linked mental decline by half, study ... variant that is good for the heart also appears to ... function and cutting the odds for Alzheimer,s disease, a study ... form of the gene, it reduces the risk of Alzheimer,s ...
... ... and Normal Lives Due to Groundbreaking Gene Therapy, , ... Cambridge, MA (Vocus) January 12, 2010 -- Genetix Pharmaceuticals, a leader ... ALD gene therapy research recently published by its collaboratiors at National Institute of Health and ...
... , WATERTOWN, Mass. , Jan. 12 ... cardiovascular system is also good for the brain, according to ... been braving cold temperatures to get in shape for the ... are encouraging others to keep in shape as well. , ...
... 5, 2010An enzyme that normally helps break down stored ... them more malignant, according to new findings by a ... has focused on the mechanisms leading to cancer formation ... says Benjamin Cravatt, chair of the Scripps Research Department ...
... , , SHENZHEN, China , ... www.htdsmedical.com ) announced that its directors have resolved that up ... sale of its MindUp division to Hiru will be distributed to ... Terry Yuan , HTDS President, said, "In our efforts to maximize ...
Cached Medicine News:Health News:Gene Variant Could Lower Alzheimer's Risk 2Health News:Gene Variant Could Lower Alzheimer's Risk 3Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 2Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 2Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 4Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 2Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 2Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: